Antithrombin–Thrombin axis (AT-IIa)

The Antithrombin–Thrombin axis is a fundamental regulatory system within the coagulation cascade that maintains the delicate balance between blood clotting and fluidity. This axis primarily involves the interaction between Antithrombin (also known as Antithrombin III), a serine protease inhibitor (serpin), and Thrombin (Factor IIa), the central effector enzyme of coagulation (StatPearls, NBK459256). Antithrombin functions as a suicide substrate that neutralizes Thrombin by forming a stable 1:1 complex, a process that is accelerated over 1,000-fold in the presence of heparin or heparin-like glycosaminoglycans (UniProt, P01008). In clinical medicine, this axis is a primary target for anticoagulation therapy; drugs like heparin and low-molecular-weight heparins act by enhancing Antithrombin's activity, while direct thrombin inhibitors like dabigatran bypass Antithrombin to block Thrombin directly (PubMed, 29044119). Conversely, novel therapeutic strategies such as fitusiran utilize RNA interference to reduce Antithrombin levels, thereby increasing Thrombin generation to treat bleeding disorders like Hemophilia A and B (NEJM, 10.1056/NEJMoa1706986). Dysregulation of this axis, whether through genetic deficiency of Antithrombin or over-activation of Thrombin, leads to severe conditions such as venous thromboembolism or disseminated intravascular coagulation.

Other names

Antithrombin III-Thrombin complexAT-III/IIa axisSERPINC1-F2 interactionHeparin-Antithrombin-Thrombin systemAntithrombin IIIThrombin

The mechanism of action involves the modulation of Thrombin activity either through the potentiation of its endogenous inhibitor, Antithrombin (e.g., via heparins), the direct competitive or non-competitive inhibition of the Thrombin active site (e.g., via direct thrombin inhibitors), or the reduction of Antithrombin protein synthesis to restore Thrombin generation in hemophilic states (e.g., via siRNA).